The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 8, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 8.
Number 5: Ontario is the most recent Canadian province to add biosimilar etanercept to its public drug plan.
Number 4: A number of stakeholders recently submitted comment letters to the Federal Trade Commission concerning competition issues in the US drug market.
Number 3: A newly published study from Sweden shows that rituximab is more effective in treating multiple sclerosis, and is subject to lower rates of discontinuation, than other disease-modifying therapies.
Number 2: Off-label use of bevacizumab has revolutionized the treatment of diabetic eye diseases, and has emerged as an important treatment modality.
Number 1: During this week’s 36th annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products that may help insulate them from biosimilar and follow-on competition.
Finally, last week, our e-newsletter asked whether you think that the United States should require records of batch and lot numbers for biosimilars in pharmacovigilance systems. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.